Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vibegron - Kyorin Pharmaceutical/Sumitomo Pharma America

Next Previous
Drug Profile

Vibegron - Kyorin Pharmaceutical/Sumitomo Pharma America

Alternative Names: Beova; GEMTESA; KRP-114V; KRP-114VP; MK-4618; OBGEMSA; RVT 901; SNV-004; URO 901

Latest Information Update: 25 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Eisai Co Ltd; Kyorin Pharmaceutical; Merck & Co; Pierre Fabre; Sinovant Sciences; Sumitomo Pharma America
  • Class Amides; Analgesics; Pyrimidines; Pyrroles; Pyrrolidines; Small molecules; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Phase II/III Neurogenic bladder
  • Phase II Pain
  • Discontinued Endocrine disorders

Most Recent Events

  • 23 Jul 2025 Launched for Overactive bladder in Thailand (PO)
  • 23 Jul 2025 Registered for Overactive bladder in Philippines, Malaysia (PO), prior to July 2025
  • 23 Jul 2025 Eisai Co., Ltd. announced the planned launches of Beova® Tablets (vibegron) in the Philippines and Malaysia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top